PEPCID AC Drug Patent Profile

Which patents cover Pepcid Ac, and when can generic versions of Pepcid Ac launch?

Pepcid Ac is a drug marketed by Kenvue Brands and J And J Consumer Inc and is included in three NDAs.

The generic ingredient in PEPCID AC is famotidine. There are eighteen drug master file entries for this compound. One hundred and thirty-seven suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pepcid Ac

A generic version of PEPCID AC was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Summary for PEPCID AC

US Patents:	0
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for PEPCID AC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	PEPCID AC	famotidine	TABLET, CHEWABLE;ORAL	020801-001	Sep 24, 1998		DISCN	Yes	No
Kenvue Brands	PEPCID AC	famotidine	TABLET;ORAL	020325-001	Apr 28, 1995		OTC	Yes	No
Kenvue Brands	PEPCID AC	famotidine	TABLET, CHEWABLE;ORAL	020801-002	Dec 17, 2007		OTC	Yes	Yes
J And J Consumer Inc	PEPCID AC	famotidine	TABLET;ORAL	020902-001	Aug 5, 1999		DISCN	No	No
Kenvue Brands	PEPCID AC	famotidine	TABLET;ORAL	020325-002	Sep 23, 2003		OTC	Yes	Yes

International Patents for PEPCID AC

See the table below for patents covering PEPCID AC around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H04211608	IMPROVED COATED DRUG AND DEVICE AND METHOD FOR ITS PREPARATION
Ireland	63265	Gelatin coated caplets and process for making same
Denmark	93580
Greece	1002292	ΜΕΘΟΔΟΙ ΠΑΡΑΣΚΕΥΗΣ ΒΕΛΤΙΩΜΕΝΩΝ ΚΕΚΑΛΥΜΕΝΩΝ ΦΑΡΜΑΚΩΝ ΚΑΙ ΣΥΣΚΕΥΗ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ. (METHODS FOR THE PREPARATION OF IMPROVED COATED MEDICAMENTS AND APPARATUS FOR MAKING SAME)
Austria	121616
Netherlands	8001361

Investment Scenario, Market Dynamics, and Financial Trajectory for PEPCID AC

Last updated: February 3, 2026

Executive Summary

PEPCID AC (famotidine) is an over-the-counter (OTC) medication used primarily for the treatment of胃酸反流,胃痛, and相关消化条件. Despite facing significant generic competition and shifting regulatory landscapes, the drug maintains a notable market position due to its established efficacy and consumer familiarity. Historically, PEPCID AC generated annual revenues upwards of $150 million pre-2020, with potential growth driven by aging populations and increasing prevalence of acid-related disorders. However, recent patent expirations, evolving market dynamics, and regulatory hurdles influence its long-term investment outlook. This analysis explores the market environment, competitive landscape, financial performance, and future projections for PEPCID AC as an investment asset.

---

What Is the Current Market Environment for PEPCID AC?

Market Overview

Parameter	Details
Global OTC胃酸药市场	Valued at approximately USD 4.5 billion in 2022, with a CAGR of 3-4%. (1)
Key Indications	GERD,胃酸反流,胃痛,胃炎,消化不良
Major Off-Patent Drugs Influence	Dexilant, Zantac (withdrawn in some markets), and generics increasing price competition. (2)
Consumer Demographics	Aging populations, increased self-medication trend, rise in GERD prevalence (up to 20-30% globally). (3)

Market Drivers

• Aging Population: Older adults are more prone to acid-related conditions, sustaining demand.
• Self-Medication Trends: Increased OTC access supports sales volume.
• Growing Awareness: Broader understanding of胃酸相关疾病 prompts self-treatment.
• Regulatory Policies: NSUs (Non-prescription status) favorable in several jurisdictions, but potential for reclassification poses risk.

Market Constraints

Constraint	Impact
Market Saturation	Pervasive generic competition depresses prices and margins.
Patent Expiration	Loss of exclusivity diminishes pricing power; increased generic penetration.
Regulatory Changes	Stringent regulations could limit OTC status or necessitate formulation modifications. (4)
Consumer Preference Shifts	Preference for newer, branded therapies may reduce OTC demand.

---

Competitive Landscape and Market Share Analysis

Key Competitors

Company	Drug/Brand Name	Market Position	Key Differentiator
Johnson & Johnson	Zantac (ranitidine)	Previously dominant, now withdrawn/limited	Replacement by other H2 antagonists
Pfizer	Pepcid (famotidine)	Leading OTC in many markets	Cost-effective, well-established drug
Takeda	Prevacid, generic versions	Prescription and OTC segments	Proton pump inhibitors (PPIs) as alternative
Bayer / Others	Omeprazole, Esomeprazole	Increasing PPI market share	Stronger acid suppression efficacy

Market Share Metrics

Brand/Drug	Approximate Market Share (2022)	Notes
Pepcid AC (famotidine)	25-30%	Leading OTC H2 blocker, steady demand
Other GSK / OTC H2s	10-15%	Market fragmentation
Prescription PPIs	40-45%	Dominant in prescription sector, reducing OTC dominance
Generics (non-branded)	10-20%	Price-driven segment, strong competition

---

Financial Performance and Trajectory

Historical Revenue and Profitability

Year	Revenue (USD millions)	Gross Margin	EBITDA Margin	Notes
2018	160	~60%	~40%	Stable sales pre-patent expiration
2019	165	~59%	~39%	Slight growth, market saturation
2020	155	~58%	~38%	Impact of COVID-19, supply chain disruptions
2021	150	~60%	~40%	Market stabilization, generic competition intensifies

Note: Specific financials are approximate averages; individual company disclosures provide detailed numbers.

Recent Trends Post-Patent Expiry

• Sales Decline: 5-10% reduction year-over-year post-2019 due to generic erosion.
• Pricing Pressure: Average retail prices declined by approximately 20% from 2018 to 2022.
• Market Penetration: Slight shift toward prescription PPI use in some regions.

Future Revenue Projections

Year	Projected Revenue (USD millions)	Assumptions
2023	135-145	Continued generic competition; moderate market decline
2024	130-140	Market saturation; slight recovery from promotional activity
2025+	Stabilization or further decline	Market adaptation; potential new formulations or indications

---

Market Dynamics Influencing Future Trajectory

Patent and Regulatory Policies

• Patent Expiry: The U.S. patent expired in 2009; subsequent formulations and new patents aimed at extending exclusivity have since expired. (5)
• OTC Regulation Trends: Regulatory agencies like FDA continue to evaluate the OTC status of existing medications, with some jurisdictions considering reclassification that could impact sales.
• Label Expansion Opportunities: New indications or formulation delivery could enhance market longevity.

Innovation and Formulation Strategies

• Combination Formulations: Potential to combine famotidine with other agents to improve efficacy or compliance.
• New Delivery Routes: Development of novel delivery systems (e.g., liquids, rapid-onset tablets) may attract consumer interest.
• Reformulation for Better Tolerability: Addressing any existing formulation limitations may provide a competitive edge.

Market Penetration of Alternatives

Alternative	Market Share Impact	Notes
PPI drugs	Increasing	Shift toward PPIs in treatment hierarchy; PPIs often prescribed over H2 antagonists
Lifestyle Modifications	Growing	Dietary and lifestyle changes reduce medication dependence
Natural & Alternative Therapies	Emerging	Increasing consumer interest in natural remedies, posing competition

---

Investment Outlook and Risks

Aspect	Implication
Market Stability	Moderate; mature OTC market with consistent demand.
Patent and Patent Challenges	Low; patent expirations have been well-anticipated and priced in.
Competitive Disruption	Moderate to high; emergence of innovative competitors or reformulations may alter dynamics.
Regulatory Environment	Uncertain; potential reclassification or restrictions could deplete sales.
Consumer Trends	Shifting preferences towards PPI and lifestyle modifications may reduce demand.

Strategic Recommendations

• Diversify Portfolio: Consider exposure to emerging gastrointestinal therapies.
• Monitor Regulatory Changes: Stay informed through FDA updates and policy shifts.
• Assess Company Pipeline: Look for firms investing in formulation innovation or alternative delivery methods.
• Evaluate OTC Market Trends: Track global OTC sales growth, especially in aging populations and emerging markets.

---

Key Takeaways

• PEPCID AC remains a significant OTC胃酸方案, but patent expirations and generics have eroded its market share.
• Market growth is constrained by intense competition from PPIs, pricing pressure, and regulatory risks.
• Long-term revenue forecasts suggest stabilization at lower levels unless innovation or new indications emerge.
• Investment strategies should prioritize companies with robust R&D pipelines, innovative formulations, or strong market positioning.
• Regulatory developments and consumer preferences will significantly influence PEPCID AC's market trajectory.

---

FAQs

1. What are the main factors that could extend PEPCID AC's market viability?
Innovation in formulations, new indications, or successful reclassification as a prescription drug could bolster sales. Additionally, targeted marketing toward aging populations may sustain demand.

2. How does PEPCID AC compare to PPI drugs in efficacy and market share?
Famotidine (PEPCID AC) provides effective acid suppression but generally less potent than PPIs like omeprazole. PPIs dominate the prescription market, making OTC famotidine less competitive in efficacy but favorable for OTC self-medication.

3. What regulatory risks exist for PEPCID AC?
Changes in OTC status, restrictions on maximum OTC dose, or reclassification as prescription-only could significantly impact revenue streams.

4. Which geographic markets present growth opportunities for PEPCID AC?
Emerging markets with growing middle classes and aging populations, such as Asia-Pacific and Latin America, offer growth potential with increasing OTC healthcare access.

5. How does formulary innovation impact the future of PEPCID AC?
New delivery systems, combination therapies, or improved tolerability can differentiate PEPCID AC from generics and competitors, potentially restoring market share.

---

References

1. MarketWatch, "Global OTC胃酸药 Market Analysis," 2022.
2. IQVIA, "Pharmaceutical Market Trends 2022."
3. Gastroenterology Journal, "Prevalence of Acid-Related Disorders," 2021.
4. FDA, "OTC Drug Monograph Modernization," 2022.
5. USPTO Patent Database, Famotidine patents overview, 2010–2022.